Skip to main content
. Author manuscript; available in PMC: 2013 May 7.
Published in final edited form as: Mol Pharm. 2012 Apr 4;9(5):1418–1424. doi: 10.1021/mp2006642

Figure 2.

Figure 2

Tumor to kidney uptake ratios of 99mTc-RGD-(Arg11)CCMSH, 99mTc-RGD-Gly-(Arg11)CCMSH, 99mTc-RGD-Lys-(Arg11)CCMSH and 99mTc-RGD-Arg-(Arg11)CCMSH at 2, 4 and 24 h post-injection. The tumor to kidney uptake ratios of 99mTc-RGD-Lys-(Arg11)CCMSH and 99mTc-RGD-Arg-(Arg11)CCMSH were calculated based on our previous reports 22,23 for comparison.